Abstract:Background: Biomedical technologies have not just improved human health but also assisted in the creation of human life. Since the first birth of a healthy baby by in vitro fertilization (IVF) 40 years ago, IVF has been the mainstay treatment for couples struggling with infertility. This technology, in addition to increasingly accessible genetic testing, has made it possible for countless couples to have children. Since CRISPR-Cas9 gene editing was described in 2015, its potential for targeting genetic diseases has been much anticipated. However, the potential of using CRISPR-Cas9 for human germline modification has led to many fears of "designer babies" and widespread concerns for the impact of this technology on human evolution and its implications in Social Darwinism. In addition to these ethical/moral concerns, there remain many unknowns about CRISPR-Cas9 technology and endless unanticipated consequence to gene editing. Methods: In this paper, we analyze the current progresses of CRISPR-Cas9 technology and discuss the theoretical advantages of certain allelic variances in the C-C chemokine receptor 5 gene (CCR5) in the setting of recent ethical/moral concerns regarding gene editing using the CRISPR-Cas9 system. Results: These uncertainties have been highlighted recently by the birth of Chinese twins whose C-C chemokine receptor 5 (CCR5) gene had been inactivated via CRISPR-Cas9 to be theoretically protective against HIV infection. CCR5 signaling is critical for the successful infection of human immunodeficiency virus (HIV) and people with homozygous inactivating CCR5-Δ32 mutations have been shown to be protected against HIV infection. Those with the CCR5-Δ32/Δ32 mutation also have greater neuroplasticity, allowing for improved recovery from neurological trauma, and decreased Chagas cardiomyopathy. However, the CCR5-Δ32/Δ32 mutation has also been associated with earlier clinical manifestations for West Nile infection, ambiguous effects on osteoclast function, and a four-fold increased mortality from influenza infection. These detrimental health impacts, in addition to the confounding factor that these CRISPR babies do not carry this exact CCR5-Δ32/Δ32 mutation, lead to many questions regarding the children's future health and the moral conundrum of their birth. The creation and birth of these babies was not completed with any scientific, ethical, or governmental oversight, which has spurned the acceleration of talks regarding global regulations for human genetic editing. Conclusions: Although we can try to regulate for ethical, health-related only use of this technology, moral and governmental oversights need to be supplemented by technical regulations. For instance, whole genome sequencing needs to be used to eliminate off-target mutations that could affect the health and safety of infants born to this process. Like Pandora's Box, we cannot pretend to forget CRISPR-Cas9 technology, all we can do is ensure a safe, moral, and equitable used of this technology.

A society-wide conversation is needed about germline genome editing using CRISPR

Human Germline Genome Editing

Focusing on Human Rights: a framework for CRISPR germline genome editing ethics and regulation

Germline genome editing of human IVF embryos should not be subject to overly stringent restrictions

CCR5-Δ32 biology, gene editing, and warnings for the future of CRISPR-Cas9 as a human and humane gene editing tool

Gene Editing Technology and Ethical Issues

CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

Emerging ethical perspectives in the clustered regularly interspaced short palindromic repeats genome-editing debate

Debating Ethical Issues in Genome Editing Technology

The History, Use, and Challenges of Therapeutic Somatic Cell and Germline Gene Editing

The Applications of the CRISPR/Cas9 Gene-Editing System in Treating Human Diseases

The Development of Gene Editing Technology and Controversial Issues: A Discussion

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Building CRISPR Gene Therapies for the Central Nervous System

Everything in moderation, even hype: learning from vaccine controversies to strike a balance with CRISPR

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Quest to use CRISPR against disease gains ground

Next-generation CRISPR technology for genome, epigenome and mitochondrial editing

CRISPR–Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications